North Brunswick, United States
Lactiga, founded in 2017, is a promising player in the Biotechnology and Pharmaceutical industries, headquartered in the United States. With the slogan "Creating the future of anti-infective therapeutics by unlocking the immunologic properties of human milk," the company is pioneering the development of patented biologics aimed at treating and preventing infections, especially for patients suffering from Primary Immunodeficiency Diseases.
As a venture-backed, NIH-funded entity, Lactiga aims to harness the therapeutic potential of human milk antibodies to combat challenging pathogens like SARS-CoV-2. The company has garnered attention through awards and coverage from notable media outlets such as the Globe & Mail, CTV, and Toronto Star, and is part of the On Deck Health (ODH2) cohort.
Its last financial boost came in the form of a $350.00K grant investment on 21 September 2022 from investors including the NJEDA, Commission on Science, Innovation and Technology, and Innovation Factory (Canada). This robust backing underscores Lactiga's potential in revolutionizing anti-infective treatments.
